WINTON GROUP Ltd Purchases New Position in Axon Enterprise, Inc $AXON

WINTON GROUP Ltd acquired a new position in shares of Axon Enterprise, Inc (NASDAQ:AXON) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 5,391 shares of the biotechnology company’s stock, valued at approximately $3,869,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. LGT Group Foundation raised its position in Axon Enterprise by 4.4% during the third quarter. LGT Group Foundation now owns 917 shares of the biotechnology company’s stock valued at $652,000 after purchasing an additional 39 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of Axon Enterprise by 0.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 54,902 shares of the biotechnology company’s stock worth $39,390,000 after purchasing an additional 454 shares during the period. Gerber Kawasaki Wealth & Investment Management increased its position in shares of Axon Enterprise by 4.3% during the 3rd quarter. Gerber Kawasaki Wealth & Investment Management now owns 6,483 shares of the biotechnology company’s stock valued at $4,652,000 after purchasing an additional 268 shares during the last quarter. Private Advisor Group LLC increased its position in shares of Axon Enterprise by 20.6% during the 3rd quarter. Private Advisor Group LLC now owns 13,326 shares of the biotechnology company’s stock valued at $9,563,000 after purchasing an additional 2,278 shares during the last quarter. Finally, PFG Advisors raised its holdings in Axon Enterprise by 4.8% during the 3rd quarter. PFG Advisors now owns 2,809 shares of the biotechnology company’s stock valued at $2,016,000 after buying an additional 129 shares during the period. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Price Performance

AXON opened at $559.06 on Tuesday. The business has a fifty day moving average of $535.65 and a 200 day moving average of $615.42. Axon Enterprise, Inc has a 52-week low of $396.41 and a 52-week high of $885.91. The company has a quick ratio of 2.29, a current ratio of 2.53 and a debt-to-equity ratio of 0.53. The stock has a market cap of $44.95 billion, a P/E ratio of 367.81, a PEG ratio of 12.25 and a beta of 1.46.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, beating the consensus estimate of $1.60 by $0.55. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.The company had revenue of $796.72 million for the quarter, compared to the consensus estimate of $755.29 million. During the same quarter in the prior year, the company posted $2.08 EPS. Axon Enterprise’s quarterly revenue was up 38.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Insider Activity at Axon Enterprise

In related news, insider Isaiah Fields sold 2,000 shares of Axon Enterprise stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $535.01, for a total transaction of $1,070,020.00. Following the completion of the sale, the insider owned 55,588 shares in the company, valued at $29,740,135.88. This trade represents a 3.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Brittany Bagley sold 2,000 shares of the business’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $580.00, for a total transaction of $1,160,000.00. Following the completion of the sale, the chief financial officer directly owned 103,501 shares of the company’s stock, valued at approximately $60,030,580. This trade represents a 1.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 26,634 shares of company stock valued at $14,963,095. Company insiders own 5.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on AXON shares. Weiss Ratings restated a “hold (c-)” rating on shares of Axon Enterprise in a research report on Monday, December 29th. Needham & Company LLC reduced their target price on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating on the stock in a research note on Friday, February 20th. UBS Group lowered their target price on shares of Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. Robert W. Baird set a $800.00 price target on shares of Axon Enterprise in a research note on Wednesday, February 25th. Finally, Craig Hallum reiterated a “buy” rating and set a $820.00 price target on shares of Axon Enterprise in a report on Wednesday, February 25th. Sixteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $762.93.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.